Background. Advances in cancer treatments continue to reduce the incidence of lymphedema. Yet, many breast cancer survivors still face long-term postoperative challenges as a result of developing lymphedema. The purpose of this study was to preliminarily evaluate The Optimal Lymph Flow program, a patient-centered education and behavioral program focusing on self-care strategies to enhance lymphedema risk reduction by promoting lymph flow and optimize body mass index (BMI). Methods. A prospective, longitudinal, quasi-experimental design with repeated-measures was used. The study outcomes included lymph volume changes by infrared perometer, and BMI by a bioimpedance device at presurgery baseline, 2-4 weeks after surgery, 6-month and 12-month follow-up. A total of 140 patients were recruited and participated in The Optimal Lymph Flow program; 134 patients completed the study with 4 % attrition rate. Results. Fifty-eight percent of patients had axillary node dissection and 42 % had sentinel lymph node biopsy (SLNB). The majority (97 %) of patients maintained and improved their preoperative limb volume (LV) and BMI at the study endpoint of 12 months following cancer surgery.
compression therapy but by maintaining The Optimal Lymph Flow exercises to promote daily lymph flow.
Conclusions. This educational and behavioral program is effective in enhancing lymphedema risk reduction. The study provided initial evidence for emerging change in lymphedema care from treatment-focus to proactive risk reduction.
Lymphedema is one of the unfortunate outcomes of breast cancer treatment since it negatively impacts survivors' overall quality of life. [1] [2] [3] Breast cancer-related lymphedema is characterized by an accumulation of lymph fluid in the interstitial spaces of the affected limb, leading to chronic ipsilateral limb swelling coupled with multiple distressing symptoms. [3] [4] [5] Breast cancer survivors who undergo breast surgery, dissection of lymph nodes and vessels, and radiation are known to have a compromised lymphatic system, leading to ineffective lymphatic drainage, thus risk for lymphedema. 6, 7 In addition to the risk factor of compromised lymphatic drainage from cancer treatment, higher body mass index (BMI) is also an established risk factor for lymphedema. [8] [9] [10] [11] Physiologically, a larger body mass creates a disproportion in lymph transport and capacity, resulting in excess extracellular fluid. 12 Women are 1.11 times more at risk for developing lymphedema with every increase of 1 kg/m 2 in their BMI. [8] [9] [10] [11] Patient education focusing on risk-reduction strategies holds great promise for reducing the risk of lymphedema. 13 Research evidence demonstrates that patient education remains an important predictor of lymphedema outcome after controlling for confounding cancer treatment-related risk factors. 13 Risk factors, such as compromised lymphatic drainage and higher BMI, may be modified through self-care strategies. Current patient education emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. 14, 15 To date, there is a paucity of high-quality evidence to support these practices that reduce the risk of lymphedema. 14, 15 One early study showed a significant decrease in limb volume (LV) using the compression garments for patients with a [3 % LV increase over a 4-week short duration. 16 Research is lacking to provide evidence to reduce the risk of or halt the progression of lymphedema through self-care strategies targeting risk factors of compromised lymphatic drainage and higher BMI. To address this important clinical need, we conducted a pilot study to preliminarily evaluate a patient-centered educational and behavioral lymphedema risk-reduction program (The Optimal Lymph Flow) focusing on promoting lymph flow and optimizing BMI over a 12-month period after cancer surgery.
METHODS

Study Design
A prospective, longitudinal, quasi-experimental design with repeated measures was used to (i) evaluate the safety, feasibility, and acceptability of The Optimal Lymph Flow Program; and (ii) preliminarily evaluate the efficacy of the program, specifically LV change and BMI. The study was approved by the Institutional Review Board at NYU Langone Medical Center.
Study Population
We recruited women who were over 21 years of age, had first time diagnosis of breast cancer (Stage I-III), and were scheduled for surgical treatment, including lumpectomy or mastectomy, sentinel lymph node biopsy (SLNB), or axillary lymph node dissection ALND). Women with metastatic cancer (Stage IV), a prior history of breast cancer and lymphedema, and bilateral breast cancer were excluded. Between April 2010 and June 2012, we prospectively enrolled 140 women and followed the participants for 12 months after surgery. All participants received the The Optimal Lymph Flow Program.
The Optimal Lymph Flow Program The Optimal Lymph Flow is a patient-centered educational and behavioral program focusing on self-care risk-reduction strategies to promote lymph flow and optimize BMI by targeting known lymphedema risk of compromised lymphatic system and high BMI. Easy-to-learn self-care strategies include shoulder mobility exercises to promote shoulder function, muscle-tightening breathing, muscle-tightening pumping exercises, and large-muscle exercises to promote lymph flow and drainage, as well as general instructions to encourage nutrition-balanced (more vegetables and fruits) and portion-appropriate diet (feeling 75 % full for each meal) to strive for maintaining preoperative BMI. Table 1 describes the self-care strategies and physiological rationales. Trained nurses delivered the intervention during a 30-min face-to-face meeting with each patient. Patients demonstrated back the shoulder exercises, muscletightening breathing, and muscle-tightening pumping exercises.
Outcome Evaluation The study outcomes were LV change by infrared perometer, and BMI by a bioimpedance device at pre-surgery baseline, 2-4 weeks after surgery, 6-month and 12-month follow-up after surgery, as well as safety, feasibility, and acceptability of The Optimal Lymph Flow Program. Lymphedema was defined as a perometer measurement of[10 % LV increase from baseline in the ipsilateral arm in comparison with the changes in the contralateral arm, using the following formula: Lymphedema = (Ipsilateral Frustum LV Follow-up / Ipsilateral Frustum LV baseline )/(Contralateral Frustum LV Follow-up /Contralateral Frustum LV baseline ). 17, 18 Because even a 5 % LV increase enables detectable differences in quality of life and symptom reporting, 4, 16, 17 participants with a perometer measurement of C5 % to \10 % LV increase during any follow-up assessment were encouraged to increase the frequency of muscle-tightening breathing and pumping exercises until the LV returned to preoperative level verified by a perometer measurement in 4 weeks. Participants with a perometer measurement C10 % LV increase during any follow-up assessment were referred to lymphedema therapy, usually consisting of complete decongestive therapy. 19 Data Collection Procedure We collected data on demographic and clinical information, LV and BMI at pre-surgery baseline, 2-4 weeks, 6 months and 12 months after surgery. An electrical bioimpedance device (InBody 520, Biospace Co., Ltd) was used to measure the participants' weight, and BMI was calculated using the formula 'weight (kg)/height (m 2 )'. Infrared Perometry 350S (Juzo, Cuyahoga Falls, OH, USA) was performed on each arm as it was held horizontally. The perometer maps a three-dimensional (3D) graph of the affected and non-affected limbs using numerous rectilinear light beams, and interfaces with a computer for data analysis and storage. A 3D limb image was generated and LV calculated. This optoelectronic method has a standard deviation of 8.9 ml (arm), less than 0.5 % of LV with repeated measuring. 16, 17 Safety of The Optimal Lymph Flow Program was assessed by asking participants if the program created any discomfort or injury to them at each follow-up visit. Feasibility of the program was evaluated in terms of intervention delivering time by the trained nurses. Acceptability of the program was assessed by asking the participants the following questions: if the program helped the participants to (i) understand how to reduce the risk of lymphedema; (ii) reduce the fear and anxiety of developing lymphedema; and (iii) develop a plan to reduce the risk of lymphedema. Acceptability of the program was also assessed by the participants' practice of the risk-reduction behaviors during the study period. A structured interview guide (Lymphedema Risk-Reduction Behavior Checklist) was used to quantitatively and qualitatively assess patients' practice of risk-reduction behaviors at the study endpoint of 12 months after surgery. 
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Data Analysis
The characteristics of participants were summarized using descriptive statistics (means, standard deviations for continuous variables, and frequency distributions and proportions for qualitative variables). Distributions of baseline patient demographic and clinical characteristics were compared for patients with SLNB and ALND using Chi-squared tests for contingency tables and one-way analysis of variance for continuous variables. All statistical tests were conducted at the 0.05 significance level (two-sided) and 95 % confidence intervals (CI) were provided for estimates.
Mixed effects regression models were used with subjectspecific intercepts (and slopes if appropriate) with fixed effects of time to evaluate the changes from baseline in outcome measures of LV and BMI over time. Participants were included as a random effect to allow for the incorporation within a subject as well as missing data over time. 23 Correlations were examined to identify potential interactions and redundancies among variables. Predictive covariates (such as age, ethnicity, lumpectomy vs. mastectomy, SNLB vs. ALND) were included in the models.
RESULTS
Participants
A total of 197 women responded to the study invitation. Of the 197 patients screened, 178 (90.4 %) were eligible for the study and 140 (78.7 %) of those eligible consented to participate in the study. Those patients who were eligible but did not enroll in the study provided the following reasons for not doing so: significant travel distance, difficulty in finding transportation or childcare, or stress from cancer diagnosis.
Among the 140 patients, 134 completed the study, with a 4 % attrition rate. Reasons for not completing the 12-month follow-up were significant travel distance (three patients), death from a cardiac-related event (one patient), and withdrawal of consent due to stress from chemotherapy (two patients). Since lymph node procedures are major risk factors for lymphedema, 3, 18 we stratified the participants into ALND (n = 81; 58 %) and SLNB (n = 59; 42 %) groups. Participants in the two groups were comparable, with no significant differences in terms of education, marital status, and employment status. Participants in the SLNB group were significantly older than those in the ALND group. Significantly more women in the ALND group had mastectomy, more lymph nodes removed, and chemotherapy. No significant differences were found between the ALND and SLNB groups in terms of body weight and BMI and radiotherapy. Cancer surgery was performed on the side ipsilateral to the dominant hand in 67 patients (48 %) and on the side of the non-dominant hand in 73 patients (52 %). Table 2 provides a summary of theses comparisons of demographic and clinical characteristics.
Lymphedema and Limb-Volume Changes
At the study endpoint of 12 months following cancer surgery, no patients in the SLNB and ALND groups exceeded a [10 % LV increase. Two patients (3 %) in the SLNB group had a 10 % LV increase at the 2-4 weeks postsurgery visit; two patients (2 %) in the ALND group had a 10 % LV increase at the 6-month follow-up. All of the four women with a 10 % LV increase at the 2-4 weeks postsurgery and at the 6-month visit decreased their LV to\5 % at the 12-month visit. Among the 12 patients (8.5 %) with a [5 % to\10 % LV increase at the 6-month follow-up, all decreased their LV to\5 % at the 12-month follow-up, but one patient sustained a 6 % LV increase. Two patients with 0 % to \5 % LV at the post-surgery visit progressed to a [10 % LV increase at the 6-month visit but decreased to \5 % at the 12-month visit; seven patients without an LV increase in the ALND group at the 6-month visit progressed to a [5 % to \10 % LV increase at the 12-month visit.
For the affected and unaffected limbs, LV decreased monotonically over time (mixed-effects regression analyses: affected p = 0.0004, unaffected p \ 0.0001), adjusted for age, ethnicity, SLNB versus ALND, and mastectomy versus lumpectomy. African American participants had the highest LV, while Asian American participants had the lowest LV for both affected and unaffected limb at baseline and at the 12-month visit (Fig. 1) .
Among the eight patients who received lymphedema therapy, two of the four patients from the SLNB group had a [10 % LV increase, while two of the four patients from the ALND group had a 10 % LV increase. Only three patients wore a compression sleeve daily and two patients used bandaging when the swelling was worse. Among 52 participants who traveled by air at least once during the 12-month study period, 50 patients traveled without wearing a compression sleeve and glove and did not develop lymphedema; among these patients, 30 patients underwent ALND. Of the remaining two patients, one who wore a compression sleeve and glove during air travel did not develop lymphedema, and the other patient, who only wore a compression sleeve, did develop lymphedema in the affected hand during the travel period. Her hand swelling returned to normal in 4 weeks after daily muscle-tightening breathing and pumping exercises.
Body Weight and Body Mass Index
Participants' body weight did not change significantly over the 12-month study period (p = 0.41 after adjustment (14) 8 (14) 11 (14) Widowed 13 (9) 9 (15) 4 (5) Single or never partnered 25 (18) 10 (17) 15 (19) Ethnicity [n (%)] Asian 18 (13) 8 (13) 10 (12) African American or Black 13 (9) 3 (5) 10 (12 for age, ethnicity, SLNB vs. ALND, and mastectomy vs. lumpectomy). Ethnicity was significantly related to weight (p \ 0.001); African American women had higher body weight on average at baseline. There was no significant change in participants' BMI over the 12-month period from pre-surgery baseline, post-surgery, 6-month and 12-month follow-up visit (adjusted for age, ethnicity, SLNB vs.
ALND, and mastectomy vs. lumpectomy; mixed effects regression analysis); participants' BMI was close at four timepoints (p = 0.67). Age and ethnicity were significantly related to BMI at pre-surgery baseline (age p = 0.03; ethnicity p \ 0.001). Older patients and African American patients had higher BMI (age p = 0.004; ethnicity p \ 0.001) (Fig. 2) .
Safety, Feasibility, and Acceptability
At each follow-up visit, no participants reported injury or discomfort associated with The Optimal Lymph Flow Program. It took about 30 min for the trained nurses to deliver the program. Among the 134 patients who completed the study, more than 90 % of participants performed the risk-reduction strategies. Quantitative and qualitative evaluation provided positive support for The Optimal Lymph Flow Program (see Table 3 ).
DISCUSSION
Annually, more than 230,000 women are diagnosed with breast cancer in the US. 20 A large number of women each year still face the lifetime risk of developing this progressive and debilitating condition, even with the most conservative estimates suggesting that 3 % of women with SLNB and 20 % of those with ALND developed lymphedema at 12 months following breast cancer surgery. 18, 21, 22 Provision of patient education and risk-reduction strategies is critical to the improvement of patients' quality of life.
Although clinical and personal risk factors have been identified, rational preventive strategies derived from scientific evidence are lacking. Consistent with previous research, 16, 18 preoperative baseline and consecutive follow-up measurements are vital to successfully detect fluid accumulation. In our study, patients were provided with their measurements at each timepoint and encouraged to continue The Optimal Lymph Flow strategies. Our study demonstrated safety, acceptance, and feasibility of selfcare behaviors to promote lymph flow and optimize BMI. This is an important initial step targeting identified lymphedema risk of compromised lymphatic system and high BMI. Our study provided initial evidence that selfcare strategies may be effective, pragmatic, and low-cost for reducing lymphedema risk. Over 50 % of breast cancer survivors were found to be exceedingly worried about their risk of developing lymphedema. 18 Over 90 % of our patients reported that The Optimal Lymph Flow Program helped them to reduce their fear and anxiety of developing lymphedema. Perhaps one of the contributions of our study is that The Optimal Lymph Flow Program has increased patients' awareness of lymphedema, demonstrated patients' willingness to perform selfcare strategies, and feeling empowered and less anxious. Such findings are clinically relevant to support that patients should be educated regarding their lymphedema risk. Furthermore, empowering patients by focusing on what patients can do rather than what patients can avoid perhaps is the key, as our patients stated in the qualitative data ( Table 3) .
The full range of factors that influence the etiology and progression of lymphedema remains unknown and this knowledge gap has hindered the development of effective risk-reduction strategies. Although some LV changes in our study might be due to the natural fluctuation during the first year of cancer surgery, in comparison to the most recent data that 3 % of women with SLNB and 20 % of those with ALND developed lymphedema with the same definition as in our study, i.e.[10 % LV increase at 12 months following breast cancer surgery, 18 no patients in our study increased [10 % LV at the 12-month follow-up. Cumulatively, only two patients with SLNB (3 %) and two patients with ALND (2 %) had measurable lymphedema ([10 % LV increase) at 2-4 weeks and at the 6-month follow-up. Research demonstrated that women with mild lymphedema are more prone to progress to severe lymphedema. 3 In our study, among the 12 patients with a[5 % to\10 % LV increase at the 6-month follow-up, all decreased their LV to \5 % at the 12-month visit, but one patient from the ALND group sustained a 6 % LV increase. Our patients demonstrated that self-care strategies helped to maintain preoperative LV and halt the progression of fluid accumulation. It should be noted that general instructions on having a nutrition-balanced and portion-appropriate diet, and physical activities daily or weekly, was effective for our patients to maintain their preoperative BMI.
We recognize that this pilot study was limited because it did not have a randomized-controlled design. The strengths of our study included well-designed intervention targeting known lymphedema risk of a compromised lymphatic system and high BMI, well-defined outcomes, adequate sample size for a feasibility study, prospective and consecutive repeated measurement at meaningful timepoints, as well as quantitative and qualitative evaluation of the program. It should be noted that the majority of patients discontinued shoulder exercises at the 12-month follow-up. Our patients perceived that either there was no need to, or forgot to, do the shoulder exercises because their shoulder and limb function returned to the pre-surgical level. One acceptance testing was to discern which behaviors were initiated, continued, or discontinued by the participants. Our data showed that perhaps shoulder exercises might be discontinued once the function of the affected shoulder and limb has returned to pre-surgical level. Nevertheless, future research requires a larger study with a randomized-controlled design to evaluate the overall effectiveness of The Optimal Lymph Flow Program and to determine the dosage and contribution of the individual component of the program. Research should continue to provide evidence on the need to avoid air travel or wear compression garments during air travel, and the ethnic differences in LV. List of Products Used No products, devices, or drugs were used or identified in the manuscript.
